#PBLS - Twitter Hashtag

about 15 hours ago

🧬 New IPO: Parabilis Medicines (#PBLS) A new IPO is now available in the Fintch app. Parabilis Medicines (formerly FogPharma) is a Cambridge, Massachusetts clinical-stage biopharmaceutical company founded in 2015. Develops Helicons - a novel class of stabilized, cell-penetrant alpha-helical peptides engineered to bind flat protein-protein interaction surfaces historically considered "undruggable". Over 10+ years has built a platform combining proprietary data, lab innovations, and AI/physics-based algorithms. CEO, Chairman, and President is Mathai Mammen, M.D., Ph.D., formerly Global Head of R&D at Johnson & Johnson. 200+ employees. Bet on: lead candidate zolucatetide (formerly FOG-001) - the world's first direct inhibitor of the β-catenin:TCF protein-protein interaction, the critical node of the Wnt/β-catenin pathway whose mutations appear in 30-40% of all cancers + clinical activity confirmed in 150+ patients in Phase 1/2 + desmoid tumors program with FDA Fast Track (Nov 2025) and FDA Orphan Drug Designation (March 2026), Phase 3 planned H1 2027 + Helicons solve three problems at once: large enough for flat PPI surfaces, small enough to penetrate cells, stable enough to resist degradation + Regeneron strategic collaboration (May 2026) worth up to $2.3B + the only publicly-traded clinical company in the stabilized cell-penetrant peptide segment with proven human activity. 📊 Key terms - Price range: $17-19 per share - Shares offered: 25,000,000 - IPO net proceeds to company: ~$413.6M at midpoint $18 - Exchange: Nasdaq Global Market | Ticker: PBLS - Pricing: June 9, 2026 | Trading: June 10, 2026 - Lock-up: 93 days 💰 Financials - Revenue: $0 - clinical stage, no commercial sales - Last private round (January 2026): $305M - oversubscribed - Regeneron partnership: $50M upfront + $75M equity in the IPO (at 90% of IPO price - a direct partner confidence signal) + up to $2.3B in potential milestones - Total raised over company history: ~$750M+ - IPO proceeds use: Phase 3 zolucatetide in desmoid tumors (launch H1 2027), continuing Phase 1/2 across FAP/HCC and other Wnt-driven tumors, advancing ERG and AR degraders toward Phase 1, β-catenin degrader program, Helicon platform, general corporate purposes 🎯 Thesis Desmoid tumors are an ultra-rare neoplasm with ~3,500 new US cases annually and no standard of care - the first approved targeted therapy holds a near-monopoly position. Beyond desmoid, the Wnt/β-catenin pathway is active in 30-40% of all cancers, making a successful β-catenin inhibitor potentially transformative across oncology - a market measured in tens of billions. Additional Phase 1/2 signals: FAP (52.2% desmoid diameter reduction plus polyp burden reduction), HCC (9-month partial response in a CTNNB1-mutant patient), MSS colorectal, ACP, and more. No direct analogs for zolucatetide - β-catenin was called a "Holy Grail" and "undruggable" since the early 1990s. Indirect desmoid competitors: sotorasib, nivolumab/immunotherapy. Cell-penetrant peptide peers (CellForce, Aileron) are earlier-stage and smaller. Key risk: $0 revenue, binary clinical/regulatory outcomes, capital-intensive Phase 3 runway. 🏛️ Joint lead bookrunners: Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities. Bookrunner: LifeSci Capital. 📅 Deadline: June 9, 2026 (inclusive) 📲 Explore the deal in the Fintch app: Download https://t.co/CqMT1GPNnI

fintchone's tweet photo. 🧬 New IPO: Parabilis Medicines (#PBLS)

A new IPO is now available in the Fintch app.

Parabilis Medicines (formerly FogPharma) is a Cambridge, Massachusetts clinical-stage biopharmaceutical company founded in 2015. Develops Helicons - a novel class of stabilized, cell-penetrant alpha-helical peptides engineered to bind flat protein-protein interaction surfaces historically considered "undruggable". Over 10+ years has built a platform combining proprietary data, lab innovations, and AI/physics-based algorithms. CEO, Chairman, and President is Mathai Mammen, M.D., Ph.D., formerly Global Head of R&D at Johnson & Johnson. 200+ employees.

Bet on: lead candidate zolucatetide (formerly FOG-001) - the world's first direct inhibitor of the β-catenin:TCF protein-protein interaction, the critical node of the Wnt/β-catenin pathway whose mutations appear in 30-40% of all cancers + clinical activity confirmed in 150+ patients in Phase 1/2 + desmoid tumors program with FDA Fast Track (Nov 2025) and FDA Orphan Drug Designation (March 2026), Phase 3 planned H1 2027 + Helicons solve three problems at once: large enough for flat PPI surfaces, small enough to penetrate cells, stable enough to resist degradation + Regeneron strategic collaboration (May 2026) worth up to $2.3B + the only publicly-traded clinical company in the stabilized cell-penetrant peptide segment with proven human activity.

📊 Key terms
- Price range: $17-19 per share
- Shares offered: 25,000,000
- IPO net proceeds to company: ~$413.6M at midpoint $18
- Exchange: Nasdaq Global Market | Ticker: PBLS
- Pricing: June 9, 2026 | Trading: June 10, 2026
- Lock-up: 93 days
💰 Financials
- Revenue: $0 - clinical stage, no commercial sales

- Last private round (January 2026): $305M - oversubscribed
- Regeneron partnership: $50M upfront + $75M equity in the IPO (at 90% of IPO price - a direct partner confidence signal) + up to $2.3B in potential milestones
- Total raised over company history: ~$750M+
- IPO proceeds use: Phase 3 zolucatetide in desmoid tumors (launch H1 2027), continuing Phase 1/2 across FAP/HCC and other Wnt-driven tumors, advancing ERG and AR degraders toward Phase 1, β-catenin degrader program, Helicon platform, general corporate purposes
🎯 Thesis
Desmoid tumors are an ultra-rare neoplasm with ~3,500 new US cases annually and no standard of care - the first approved targeted therapy holds a near-monopoly position. Beyond desmoid, the Wnt/β-catenin pathway is active in 30-40% of all cancers, making a successful β-catenin inhibitor potentially transformative across oncology - a market measured in tens of billions. Additional Phase 1/2 signals: FAP (52.2% desmoid diameter reduction plus polyp burden reduction), HCC (9-month partial response in a CTNNB1-mutant patient), MSS colorectal, ACP, and more. No direct analogs for zolucatetide - β-catenin was called a "Holy Grail" and "undruggable" since the early 1990s. Indirect desmoid competitors: sotorasib, nivolumab/immunotherapy. Cell-penetrant peptide peers (CellForce, Aileron) are earlier-stage and smaller. Key risk: $0 revenue, binary clinical/regulatory outcomes, capital-intensive Phase 3 runway.

🏛️ Joint lead bookrunners:
Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities. Bookrunner: LifeSci Capital.

📅 Deadline: June 9, 2026 (inclusive)
📲 Explore the deal in the Fintch app:

Download
https://t.co/CqMT1GPNnI

0

47

keh_ke_lenge @Kehkelenge1107

about 1 month ago

Jab pooche kaun hai best? Mirror: It’s you bhai 🪞 Helmet: It’s you bhai 🪖 Crowd: It’s you bhai 🔥 PBKS era has arrived 👑 #PBLS

1

2

0

22

若者防災協議会 @Wakamonobousai

3 months ago

【保護者の方向け体験会】「人工呼吸が鍵になる⁉︎こどもの救命法」 2月18日に神戸市本庄児童館で、保護者の方向けの小児救命講習を開催しました。我が子のもしもに備えて、学んでいただきました。 #BLS #PBLS #小児 #救命講習 #神戸 #若者防災協議会

Wakamonobousai's tweet photo. 【保護者の方向け体験会】
「人工呼吸が鍵になる⁉︎こどもの救命法」

2月18日に神戸市本庄児童館で、保護者の方向けの小児救命講習を開催しました。

我が子のもしもに備えて、学んでいただきました。

#BLS #PBLS #小児 #救命講習 #神戸 #若者防災協議会 https://t.co/sq0dzNE3OV

1

6

5

0

366

Andrea Wright @wrightway99

4 months ago

Spent the day supporting @Stallions415 hard working and dedicated teachers with #STEM collaborative planning. We discussed ways to integrate and elevate their #PBLs. They are also prepping for an upcoming STEM Night. @DCSDHorizon @dcsdctae @DCSDSTEM @YvonneTBrowder #stemedu

0

3

0

755

Andrea Wright @wrightway99

7 months ago

SO to the team at #LovinES in @GwinnettSchools. @DCSDSTEM schools attended a #STEM visit there today, and were impressed by the day to day instruction, student engagement, and #PBLs. Keep up the great work! PS - We loved the parking signs! @STEMGeorgia.

wrightway99's tweet photo. SO to the team at #LovinES in @GwinnettSchools. @DCSDSTEM schools attended a #STEM visit there today, and were impressed by the day to day instruction, student engagement, and #PBLs. Keep up the great work!

PS - We loved the parking signs!

@STEMGeorgia. https://t.co/J1uG6dYlWV

0

5

1

0

190

Cees van Romburgh @NLRCFirstAid

8 months ago

Samengevat de veranderingen bij de reanimatie van kinderen bij de update van de Nederlandse Richtlijnen Reanimatie 2025 @Reanimatieraad #RESUS25 #PBLS #EHBO

NLRCFirstAid's tweet photo. Samengevat de veranderingen bij de reanimatie van kinderen bij de update van de Nederlandse Richtlijnen Reanimatie 2025 @Reanimatieraad #RESUS25 #PBLS #EHBO https://t.co/eXZF7LVEDE

0

3

0

126

Cees van Romburgh @NLRCFirstAid

8 months ago · Leidschendam-Voorburg

Het was een 2de interessante dag vandaag @ERC_resus #CPR #PBLS #RESUS25

0

3

1

0

136

miwa｜Simple Style💫 @miwa_spring33

10 months ago

感動がよみがえる🥹 #大阪関西万博 #EXPO2025 #PBLS

ときなおみ🍎🌏 @naomi_toki

10 months ago

✨いのち輝く尊厳が生みだす平和✨ 　　　ダイジェスト《前編》　　　　PBLS 　【2025大阪・関西万博】　　　　　 🎥https://t.co/8CNhgQWBAZ あの感動をもう１度✨

0

7

0

383

0

4

0

283

山中浩司#鬱自殺殺人ゼロ尊厳溢れる社会へ @sanchu1007

10 months ago

令和哲学チャンネルに4/18万博イベントのダイジェストが公開されました！🚩🚩 感動が甦る #BESTBEING #PBLS #大阪万博2025

1

4

0

90

N看護師 @ficklenurse

11 months ago

換気の重要性を再認識子どもにはマスト HandsOnlyも良い？と言われる成人に院内医療従事者としてはどんな患者に換気が必要？市民にも胸骨圧迫、AEDと言う言葉がありふれた時代に北九州ではプロのスキルと判断が出来る教育を開催 https://t.co/52hVGI3LKF #JReSS #BLS #PBLS #人工呼吸 #新人看護師

0

3

1

0

358

N看護師 @ficklenurse

11 months ago

私も拝聴しましたがこれってBLS横浜さんがずっと言っていた事コロナの蘇生教育でアフターコロナも人工呼吸しないとデータがなんと、近しい家族すらやらないと誤った蘇生教育の成果か #PBLS #人工呼吸

BLS横浜

@BLSyokohama

11 months ago

蘇生科学シンポジウム、今回は日本小児救急医学会学術集会との併催で、最後の話題は小児BLS。とにかく強調されているのは、人工呼吸の大切さ。 BLSの裾野を広げるために胸骨圧迫を強調し過ぎた煽りを受けて小児救命に不利益を受けている現状が報告されていました。

0

36

9

2

3K

0

9

4

1

2K

N看護師 @ficklenurse

11 months ago

東京に行く予定が出来たから J-ReSSでも参加してくるか #JRC #BLS #ALS #PBLS

JRC 日本蘇生協議会 @JpnRessCouncil

11 months ago

日本蘇生科学シンポジウム（J-ReSS）は今週末7月5日土曜日に虎ノ門ヒルズフォーラムで開催予定です。テーマ：　「救命の連鎖」を科学する〜予防から恢復まで〜参加費：　3000円（J-ReSSのみ）ホームページ：　https://t.co/uFQu6FVTiz ぜひ多くのご参加をお待ちしております。

JpnRessCouncil's tweet photo. 日本蘇生科学シンポジウム（J-ReSS）は今週末7月5日土曜日に虎ノ門ヒルズフォーラムで開催予定です。
テーマ：　「救命の連鎖」を科学する〜予防から恢復まで〜
参加費：　3000円（J-ReSSのみ）
ホームページ：　https://t.co/uFQu6FVTiz
ぜひ多くのご参加をお待ちしております。 https://t.co/a1D9DbykeP

0

14

5

1

2K

0

4

0

507

山中浩司#鬱自殺殺人ゼロ尊厳溢れる社会へ @sanchu1007

12 months ago

TPP Together for Peace Power2025 戦争反対ではなく戦争不可能へ 20年以上の歴史あるイベントが来週あります🙌 今回も4月の万博同様アーティスト田中裕子さんのバックでサポートダンサーとして出させてもらいます🙆🙆 #TPP #PBLS #nTech

sanchu1007's tweet photo. TPP Together for Peace Power2025
戦争反対ではなく戦争不可能へ
20年以上の歴史あるイベントが来週あります🙌
今回も4月の万博同様アーティスト田中裕子さんのバックでサポートダンサーとして出させてもらいます🙆🙆

#TPP
#PBLS
#nTech https://t.co/xj8tXrfJmf

1

9

0

224

sports news @CricUniverse7

about 1 year ago

#PBKS beat #LSG by a margin of 37 runs. AYUSH BADONI scored brilliantly 74(40) runs. Now #PBLS moved in to the 2nd Position with 15 Points. Congratulations 👏🎉👏 PBKS #PBKSvsLSG #KKRvsRR #TATAIPL2025 #PremierLeague #BREMUN #CHELIV #BreakingNews #SweetAshley #zelena

0

3

1

0

419